Puerarin

Puerarin Struktur
3681-99-0
CAS-Nr.
3681-99-0
Englisch Name:
Puerarin
Synonyma:
PSYCHOSINE;DAIDZEIN-8-C-GLUCOSIDE;Purerarin;PUERARIN EXTRACT;Puerain;PUERARIN;Kakonein;Puerqarin;Puerarine;Daidzeine
CBNumber:
CB0732521
Summenformel:
C21H20O9
Molgewicht:
416.38
MOL-Datei:
3681-99-0.mol

Puerarin Eigenschaften

Schmelzpunkt:
187-189°C
Siedepunkt:
688.0±55.0 °C(Predicted)
Dichte
1.614±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
pka
6.46±0.20(Predicted)
Aggregatzustand
Powder
Farbe
White to Off-white
Wasserlöslichkeit
Soluble in DMSO or DMF. Slightly soluble in water or ethanol
maximale Wellenlänge (λmax)
303nm(MeOH)(lit.)
BRN 
64198
InChIKey
HKEAFJYKMMKDOR-NCHCSYJDSA-N
SMILES
OC1=CC=C2C(C(C3C=CC(O)=CC=3)=COC2=C1[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)=O |&1:18,19,20,22,24,r|
LogP
0.408 (est)
CAS Datenbank
3681-99-0(CAS DataBase Reference)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher F,C
R-Sätze: 11-34
S-Sätze: 22-24/25-45-36/37/39-26-16
WGK Germany  3
RTECS-Nr. UO5216000
10
HS Code  29389090
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
H335 Kann die Atemwege reizen. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 3 (Atemwegsreizung) Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" />
Sicherheit
P261 Einatmen von Staub vermeiden.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Puerarin Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R11:Leichtentzündlich.
R34:Verursacht Verätzungen.

S-Sätze Betriebsanweisung:

S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S16:Von Zündquellen fernhalten - Nicht rauchen.

Beschreibung

Puerarin, also known as pueraria flavonoids, is a kind of flavonoid glycoside extracted from the roots of Pueraria alba or Pueraria thomsonii and is also one of the main effective ingredients of Pueraria lobata. That Pueraria lobate was used to treat diseases has already been recorded in China’s ancient medical books such as Shen Nong’s Materia Medica, Treatise on Miscellaneous Diseases and Medical Dictionary.
Kanzu root is widely distributed in our country and of rich resources. It has been reported that puerarin could be extracted from Pueraria lobata (Wild.) Ohwi, Radix Pueraria thomsonii, Pueraria omeiensiswanget Tang, Pueraria edulis Pamp and Pueraria phaseoloides, but the content of puerarin differs.
Pueraria has a great value for nutrition and medicine and was considered the south ginseng of China. Puerarin has been widespread concerned over our country for its use of food and medicine in recent years.

Chemische Eigenschaften

White powder

Physikalische Eigenschaften

Appearance: White to light-yellow crystalline powder. Solubility: Soluble in methanol, freely soluble in ethanol, slightly soluble in water, insoluble in chloroform and ether. Melting point: 187–189?°C.

History

In 1959, Japanese chemist Shibata Shoji first studied the chemical production of pueraria root, indicating that isoflavones are the main active ingredients of pueraria root, including puerarin, daidzin and daidzein . Then in 2003, David Lee first total synthesized analogical puerarin . And it was in 1974 that puerarin was first extracted by Fang Qicheng and other chemists in China . Due to its strong activity of anti-cardiovascular and anti-cerebrovascular ischemia and hypoxia, expanding the coronary artery and cerebrovascular, reducing myocardial oxygen consumption, and improving myocardial systolic and microcirculation function, puerarin was approved for clinical use by the Ministry of Health in 1993.
In recent years, researchers have synthesized a series of puerarin derivatives, and active research showed that the part of the puerarin derivatives has a good biological activity and bioavailability. In a new dosage form research, researchers have developed several types of dosage forms such as quickrelease solid dispersions, solid from microemulsion preparation, etc., which greatly increase the solubility of puerarin, thus improving bioavailability. In recent years,the research on crystal drug has opened up new ways for the application of puerarin.

Verwenden

Puerarin is a naturally occuring isoflavonoid derived from Chinese medical herb kudzu root and has been used for the treatment of various cardiovascular diseases. Recent sutdies have shown the potenti al of puerarin treatment as a novel approach to lowering the risk of or improving function in ischemia-reperfusion brain injury-related disorders.

Definition

ChEBI: A hydroxyisoflavone that is isoflavone substituted by hydroxy groups at positions 7 and 4' and a beta-D-glucopyranosyl residue at position 8 via a C-glycosidic linkage.

Indications

At present the most widely used medicinal formulation of puerarin in clinical application is puerarin injection, with more than 90 enterprises producing it. The injection was mainly used for the treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal movement, vein occlusion, sudden deafness and other diseases. Another dosage form of puerarin is eye drops for the treatment of primary open-angle glaucoma, ocular hypertension, primary angle closure glaucoma and secondary glaucoma. In addition, there are puerarin tablets and puerarin capsules, belonging to the health-care product.

Pharmakologie

Contemporary pharmacological research has demonstrated that puerarin has wide pharmacological activities on the cardiovascular system, nervous system, liver impairments, osteoporosis and hangover .
The clinical and experimental researches have shown that puerarin has a significant role in the prevention of cerebral vascular disease, which can expand the coronary artery and improve the metabolism of an ischemic heart muscle, improving brain circulation, increasing cerebral blood flow and reducing blood volume and heart rate. There is good control of puerarin on myocardial ischemia and cerebral ischemic disease.
A large number of experiments have proved that puerarin can promote the glucose and lipid metabolism and reduce blood sugar and blood lipid. The protection of puerarin on diabetes was attributed to its functions on inhibiting apoptosis and oxidative stress.
Puerarin have protection efficacy on liver damage induced by chemical substances, alcohol, surgery and other experimental damage. This effect is closely related to the antioxidant effect, resisting lipid peroxidation, inhibiting platelet aggregation and improving circulation.
Puerarin can also improve the eye microcirculation obviously and reduce the pressure of the eyes, thus acting obvious therapeutic effect on glaucoma. In addition, it has a variety of preparations, such as liquors, which are still under development.

Clinical Use

Currently, puerarin is used clinically for the treatment of hypertension, coronary heart disease, angina pectoris, arrhythmia, myocardial infarction, ischemic cerebrovascular disease, retinal arteriovenous obstruction, sudden deafness, diabetes complications, dizziness and other diseases. Besides, it also is used to treat chronic pharyngitis, cerebral infarction and Parkinson’s syndrome.
However, puerarin also has adverse reactions in clinical therapy. Fever is the main symptom. In addition, allergic dermatitis, anaphylactic shock, laryngeal oedema, increased transaminase, gastrointestinal bleeding, haemolysis phenomenon and kidney damage occurred occasionally, and these symptoms disappeared after withdrawal of the medication.

Puerarin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Puerarin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 594)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd
+8618829768577
gao490372054@gamil.com China 1250 58
Chengdu ChenLv Herb Co.,Ltd
+undefined13608205856
maryextract@126.com China 127 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578
sales@hbmojin.com China 12457 58
Wuhan Han Sheng New Material Technology Co.,Ltd
+8617798174412
admin01@hsnm.com.cn China 2118 58
Shaanxi Haibo Biotechnology Co., Ltd
+undefined18602966907
qinhe02@xaltbio.com China 1000 58
Chongqing Zhihe Biopharmaceutical Co., Ltd.
+86-18580541567 +86-17782035140
sales@zhswyy.com China 338 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652
info@fdachem.com China 7613 58
Shanghai Affida new material science and technology center
+undefined15081010295
2691956269@qq.com China 359 58
BINBO BIOLOGICAL CO.,LTD
+8618629063126
info@binbobiological.com China 268 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21695 55

3681-99-0()Verwandte Suche:


  • Puerain
  • PUERARIN(P)
  • 8-beta-d-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-on
  • Puerqarin
  • PUERARIN WITH HPLC
  • PUERARIN
  • 8-GLUCOSYLDAIDZEIN
  • 7-HYDROXY-3-[4-HYDROXYPHENYL]-1-BENZOPYRAN-4-ONE 8-[BETA-D-GLUCOPYRANOSIDE
  • PUERARIAROOT.P.E
  • 4H-1-Benzopyran-4-one,8-β-D-glucopyranosyl-
  • 7-hydroxy-3-(4-hydroxyphenyl)-
  • 8-β-D-Glucopyranosyl-3-(4-hydroxyphenyl)-7-hydroxy-4H-1-benzopyran-4-one
  • Puerarin, froM Puerariae Radix
  • Kakonein
  • PEONIDIN-3-O-RUTINOSIDE CHLORIDE(RG)
  • Pueraria Root Flavone
  • Puerarin ,98%
  • 8-(beta-D-Glucopyranosyl)-4',7-dihydroxyisoflavone
  • Puerarin (Kakonein)
  • 8-C-glucoside
  • 8-Glucopyranosyldaidzein
  • 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-
  • PUERARIN >= 98.0% (HPLC)
  • 8-(β-D-Glucopyranosyl)-4',7-dihydroxyisoflavone
  • 7,4'-DIHYDROXY-8-C-GLUCOSYLISOFLAVONE
  • 8-(beta-d-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
  • 4',7-DIHYDROXY-8-C-GLUCOSYLISOFLAVONE
  • Puerarine
  • PuerariaExtract
  • Puerarin std.
  • 8-(β-d-glucopyranosyl-7-hydroxy-3- (4-hydroxyphenyl)-4h-1-benzopyran-4-one
  • Puerarin>
  • Puerarin RS
  • Puerarin8-(beta-D-Glucopyranosyl-7
  • Puerarin USP/EP/BP
  • 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
  • 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6 R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-4 H-chromen-4-one
  • TIANFU-CHEM CAS:3681-99-0 Puerarin
  • Daidzeine
  • Puerarin, 98%, from Pueraria edulis Pamp.
  • 7-hydroxy-3-(4-hydroxyphenyl)-8-((2S,3R,4R,5S,6R)- 3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yl)-4H-chromen-4-one
  • 7-hydroxy-3-(4-hydroxyphenyl)-8-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-1-benzopyran-4-one
  • Puerarin, 98%, from Puerariae Radix
  • Puerarta Lbata Extract
  • Puerarin 3681-99-0
  • Soluble PUERARIN, Liposomal PUERARIN, PUERARIN NanoEmulsion, NanoActive PUERARIN
  • DAIDZEIN-8-C-GLUCOSIDE
  • PSYCHOSINE
  • PUERARIN EXTRACT
  • Purerarin
  • Kudzuvine Root extract
  • puerarin Daminozide
  • Puerarin (6CI, 7CI, 8CI)
  • 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-
  • 3681-99-0
  • Food & Beverage Standards
  • Food Residue Analysis
  • Chromatography
Copyright 2019 © ChemicalBook. All rights reserved